Trial
NCT06290622
PD-1, LAG-3 and TIM-3 Checkpoint Blockade in DLBCL
Phase IWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
University of Alabama at Birmingham
Collaborators
—
Condition
Diffuse Large B Cell Lymphoma
Intervention
Retifanlimab, INCAGN02385, INCAGN02390
Why stopped
Investigator request to no longer pursue this study. Lack of support from drug company. This trial never opened. Withdrew IND.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-05-06